Advertisement
Advertisement
TOPIC

China’s private sector

China’s private sector
The latest news, analysis and opinion on China’s private sector. In-depth analysis, industry insights and expert opinion.
Luxshare Precision Industry has passed a regulatory hurdle to list in Hong Kong. Photo: Getty Images
Stocks

iPhone supplier Luxshare passes key hearing for Hong Kong listing

The firm, a key supplier for AirPods and iPhones, is a step closer to joining other mainland Chinese tech heavyweights in HKEX listing.

Biomedicine: Industry Trends

China is fretting over a demographic crisis – but what companies might benefit?

Biomedicine: Companies

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

Robotics

Apple supplier Lingyi seeks US$1.1 billion Hong Kong IPO to fund AI and robotics

The Shenzhen-listed components maker is using a Hong Kong float to fund its push into AI servers, smart glasses and robotics.

Lingyi’s ‘Lingyue’ humanoid robots perform at an Honor flagship store launch in Shenzhen. Photo: Getty Images
Biomedicine: Companies

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

Mainland China

From Alo to Texas Chicken, foreign brands bet on China despite stiff rivalry

For premium and niche brands, China still represents a growth opportunity in a fast-changing consumer market.

Advertisement
Advertisement
Advertisement
Mainland China

Can Pop Mart sustain the Labubu juggernaut as China sales cool?

Analysts warn of rising sales pressure as China demand tapers off, even as Pop Mart bets on new launches and overseas growth.

No signs of mollification: Pop Mart’s Molly figures stand their ground as the company records its first year-on-year decline in domestic online sales since 2024. Photo: AP
Food delivery apps

China proposes ban on ‘irrational’ food-delivery subsidies to end price wars

Regulators target predatory pricing and merchant coercion, with new rules requiring that tech giants disclose subsidy data and not disrupt the market.

China economy

Global brands in China seek local partners amid market squeeze

Slower consumer spending and cutthroat competition are pushing global brands such as Pizza Hut and Starbucks to reshape their China business.

Mainland China

Yum China rolls out the dough for mainland’s Pizza Huts in US$1.2b deal

Though the acquisition would mean full ownership of the restaurant brand in mainland China, the company’s stock price fell after the announcement.

Once the transaction closes, Yum China will transition from Pizza Hut’s exclusive licensee in mainland China to the brand’s owner. Photo: Shutterstock
Mainland China

Smart-driving chips: the weapon of choice in China’s EV tech war

Carmakers strive for more control over computing hardware to reduce reliance on Nvidia and Horizon Robotics.

Chinese electric-vehicle makers are designing their own smart-driving chips, the latest weapon of choice in the highly competitive sector. Photo: Weibo
Mainland China

Natural diamond firms turn to blockchain traceability amid lab-grown competition

The Gemological Institute of America is set to acquire a stake in Tracr, which has developed a blockchain platform to trace diamond origin.

videocam
China's economic recovery

‘Not a crackdown’: China regulators eye neutral enforcement in shift from 2021

Increased scrutiny of tech giants and finance firms seen as end to the era of administrative restraint as officials move to curb monopolies and price wars.

Biomedicine: Companies

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

Chinese companies now account for about half of all global biotechnology business development deals. Photo: Shutterstock
Biomedicine: Companies

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.

The cost advantages of Chinese pharmaceuticals mean they still appeal to multinational drug makers despite US security concerns. Photo: TNS
Microsoft

Microsoft cuts hundreds of mainland cloud jobs, as China, US tighten data laws

The firm is laying off some employees at its cloud unit amid ongoing restrictions on cross-border data flows between the two countries.

United States

China market is the ‘world’s toughest gym’ for global brands: McKinsey

Innovation, speed, and entrepreneurial agility are needed in China; foreign firms must adapt or lose ground, says McKinsey’s Joe Ngai.

9
Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

Chinese pharmaceutical companies may expand into international markets in the coming years. Photo: Shutterstock
Biomedicine: Companies

With AI able to predict disease, can we treat ageing like a ‘bug’ in the system?

AI is transforming longevity as companies like METiS TechBio and Human Longevity use algorithms to combat ageing and predict health risks.

Mainland China

The big scoop: lemon tea chain to revamp Haagen-Dazs’ struggling China business

General Mills is offloading the ice cream brand’s mainland China stores, as foreign businesses revamp models amid heated domestic competition.

videocam
Biomedicine: Companies

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Illustration of a healthy lung and a smoker's lung. Photo: Shutterstock
Biomedicine: Companies

China’s biotech boom drives surge in home-grown innovative drug approvals

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

Chinese biotech firms struck a record US$60 billion in cross-border licensing deals in the first quarter of 2026. Photo: Getty Images
Biomedicine: Companies

Insilico, US partner to build AI models predicting disease decades ahead

Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research.

Guangzhou

A new battlefront for KFC and its Chinese rivals: the lighter meal

Big-name fast-food chains are seeking to capitalise on a surge in demand in China for lighter meals.

Mainland China

Baidu says AI now primary business driver despite 2% drop in first-quarter revenue

Analysts expect the company’s AI marketing services base to steadily grow to reduce declines in advertising revenue and boost profits.

videocam
The Baidu logo is displayed at the company building in Shenzhen. Photo: Getty Images
China stock market

‘Explosive’: why China’s gold recycling industry is growing at record speed

More than half of the country’s gold recycling firms are less than three years old.

A woman shows a gold bar before selling in a smart gold store machine placed in a shopping mall in Shanghai on January 29. Photo: AFP
Banking & finance

China’s credit demand weak in April despite policy support, strong industry

Lending growth slows as borrowing demand from households and businesses remains weak.

China-EU relations

German firms in China more optimistic despite Iran war, trade headwinds: survey

Expectations for growth, profits and investment are all up, despite geopolitical turbulence.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement